胰高血糖素样肽-1受体激动剂治疗2型糖尿病的新进展

doi:10.5246/jcps.2024.08.050

摘要/Abstract

摘要：

胰高血糖素样肽-1受体激动剂(GLP-1RA)是一种新型降糖药物, 因其安全性、降糖效能和代谢优势在2型糖尿病的治疗中得到了广泛认可。其作用机制主要包括促进胰岛素释放、抑制胰高血糖素分泌、增强胰岛细胞功能、抑制食欲、延缓胃排空等。本文综述了不同类型GLP-1RA的临床证据, 这些证据表明GLP-1RA在控制血糖、减重以及心血管和肾脏保护方面都有显著的效果。尽管如此, 已有一些报道显示出GLP-1RA的不良反应, 如胰腺炎和肠梗阻等, 需要引起临床医生的注意。总之, GLP-1RA在2型糖尿病的治疗中具有巨大的潜力, 显示出优秀的心血管和肾脏获益作用

关键词: 胰高血糖素样肽-1受体激动剂, 2型糖尿病, 代谢性疾病

Abstract:

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel hypoglycemic agents that have garnered widespread acceptance in the treatment of type 2 diabetes, largely attributed to their safety profile, potent hypoglycemic effects, and metabolic advantages. Their primary mechanisms of action encompass promoting insulin release, inhibiting glucagon secretion, bolstering pancreatic islet cell function, curbing appetite, and slowing gastric emptying. This article delves into the clinical evidence underscoring the efficacy of various GLP-1RAs. Notably, these agents have demonstrated marked improvements in glycemic control, significant weight reduction, and substantial cardiovascular and renal protection. Nonetheless, certain adverse effects of GLP-1RAs, such as pancreatitis and intestinal obstruction, have been reported, warranting vigilant monitoring by healthcare professionals. In sum, GLP-1RAs hold significant promise in the management of type 2 diabetes, offering notable cardiovascular and renal advantages.

Key words: Glucagon-like peptide-1 receptor agonist, Type 2 diabetes, Metabolic diseases

Supporting:

彭雅萍, 付颖. 胰高血糖素样肽-1受体激动剂治疗2型糖尿病的新进展[J]. 中国药学(英文版), 2024, 33(8): 667-685.

Yaping Peng, Ying Fu. Advancements in glucagon-like peptide-1 receptor agonist therapy for type 2 diabetes[J]. Journal of Chinese Pharmaceutical Sciences, 2024, 33(8): 667-685.

图/表 2

参考文献 82

[1]	Bommer, C.; Sagalova, V.; Heesemann, E.; Manne-Goehler, J.; Atun, R.; Bärnighausen, T.; Davies, J.; Vollmer, S. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018, 41, 963–970.
[2]	Papatheodorou, K.; Papanas, N.; Banach, M.; Papazoglou, D.; Edmonds, M. Complications of diabetes 2016. J. Diabetes Res. 2016, 2016, 6989453.
[3]	Shao, H. Incretin-based therapies for type 2 diabetes with nonalcoholic fatty liver disease: a systematic review and meta-analysis. J. Chin. Pharm. Sci. 2016, 25, 206–214.
[4]	Li, S.Y.; Vandvik, P.O.; Lytvyn, L.; Guyatt, G.H.; Palmer, S.C.; Rodriguez-Gutierrez, R.; Foroutan, F.; Agoritsas, T.; Siemieniuk, R.A.C.; Walsh, M.; Frere, L.; Tunnicliffe, D.J.; Nagler, E.V.; Manja, V.; Åsvold, B.O.; Jha, V.; Vermandere, M.; Gariani, K.; Zhao, Q.; Ren, Y.; Cartwright, E.J.; Gee, P.; Wickes, A.; Ferns, L.; Wright, R.; Li, L.; Hao, Q.K.; Mustafa, R.A. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021, 373, n1091.
[5]	Cantini, G.; Mannucci, E.; Luconi, M. Perspectives in GLP-1 research: new targets, new receptors. Trends Endocrinol. Metab. 2016, 27, 427–438.
[6]	Sandoval, D.A.; D’Alessio, D.A. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 2015, 95, 513–548.
[7]	Christian, A.; Preman, K.; Pedersen Lene, R.; Nielsen Olav, W.; Kristiansen Ole, P.; Mogens, F.; Sten, M.; Ahmad, S.; Haugaard Steen, B. Liraglutide effects on beta-cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. Diabetes Obes. Metab. 2017, 19, 850–857.
[8]	van Raalte, D.H.; Bunck, M.C.; Smits, M.M.; Hoekstra, T.; Cornér, A.; Diamant, M.; Eliasson, B.; Marja-RiittaTaskinen, Heine, R.J.; Smith, U.; Yki-Järvinen, H. Mari, A. Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial. Eur. J. Endocrinol. 2016, 175, 345–352.
[9]	Kimura, T.; Obata, A.; Shimoda, M.; Hirukawa, H.; Kanda-Kimura, Y.; Nogami, Y.; Kohara, K.; Nakanishi, S.; Mune, T.; Kaku, K.; Kaneto, H. Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure. Diabetes Metab. 2018, 44, 250–260.
[10]	Cui, Q.L.; Liao, Y.J.; Jiang, Y.J.; Huang, X.H.; Tao, W.H.; Zhou, Q.Q.; Shao, A.N.; Zhao, Y.; Li, J.; Ma, A.R.; Wang, Z.H.; Zhang, L.; Yang, Z.Y.; Liang, Y.N.; Wu, M.L.; Yang, Z.Y.; Zeng, W.; Wang, Q.H. Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. J. Endocrinol. 2021, 248, 145–154.
[11]	Kapitza, C.; Dahl, K.; Jacobsen, J.B.; Axelsen, M.B.; Flint, A. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017, 60, 1390–1399.
[12]	Mari, A.; Del Prato, S.; Ludvik, B.; Milicevic, Z.; de la Peña, A.; Shurzinske, L.; Karanikas, C.A.; Pechtner, V. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes. Diabetes Obes. Metab. 2016, 18, 834–839.
[13]	Mikkelsen, R.R.; Hundahl, M.P.; Torp, C.K.; Rodríguez-Carrio, J.; Kjolby, M.; Bruun, J.M.; Kragstrup, T.W. Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: a bedside-to-bench approach. Eur. J. Pharmacol. 2022, 925, 174998.
[14]	Luotola, K. IL-1 receptor antagonist (IL-1Ra) levels and management of metabolic disorders. Nutrients. 2022, 14, 3422.
[15]	Dandona, P.; Ghanim, H.; Abuaysheh, S.; Green, K.; Dhindsa, S.; Makdissi, A.; Batra, M.; Kuhadiya, N.D.; Chaudhuri, A. Exenatide increases IL-1RA concentration and induces nrf-2-keap-1-regulated antioxidant enzymes: relevance to β-cell function. J. Clin. Endocrinol. Metab. 2018, 103, 1180–1187.
[16]	Ding, M.; Fang, Q.H.; Cui, Y.T.; Shen, Q.L.; Liu, Q.; Wang, P.H.; Yu, D.M.; Li, C.J. Liraglutide prevents β-cell apoptosis via inactivation of NOX2 and its related signaling pathway. J. Diabetes Complicat. 2019, 33, 267–277.
[17]	Zummo, F.P.; Cullen, K.S.; Honkanen-Scott, M.; Shaw, J.A.M.; Lovat, P.E.; Arden, C. Glucagon-like peptide 1 protects pancreatic β-cells from death by increasing autophagic flux and restoring lysosomal function. Diabetes. 2017, 66, 1272–1285.
[18]	Hjerpsted, J.B.; Flint, A.; Brooks, A.; Axelsen, M.B.; Kvist, T.; Blundell, J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes. Metab. 2018, 20, 610–619.
[19]	Voronova, V.; Zhudenkov, K.; Penland, R.C.; Boulton, D.W.; Helmlinger, G.; Peskov, K. Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: a quantitative assessment using an integrative systems pharmacology model. Diabetes Obes. Metab. 2018, 20, 2034–2038.
[20]	Halawi, H.; Khemani, D.; Eckert, D.; O’Neill, J.; Kadouh, H.; Grothe, K.; Clark, M.M.; Burton, D.D.; Vella, A.; Acosta, A.; Zinsmeister, A.R.; Camilleri, M. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol. Hepatol. 2017, 2, 890–899.
[21]	Gabery, S.; Salinas, C.G.; Paulsen, S.J.; Ahnfelt-Rønne, J.; Alanentalo, T.; Baquero, A.F.; Buckley, S.T.; Farkas, E.; Fekete, C.; Frederiksen, K.S.; Helms, H.C.C.; Jeppesen, J.F.; John, L.M.; Pyke, C.; Nøhr, J.; Lu, T.T.; Polex-Wolf, J.; Prevot, V.; Raun, K.; Simonsen, L.; Sun, G.; Szilvásy-Szabó, A.; Willenbrock, H.; Secher, A.; Knudsen, L.B.; Hogendorf, W.F.J. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020, 5, e133429.
[22]	Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.E.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S.; Steinberg, W.M.; Stockner, M.; Zinman, B.; Bergenstal, R.M.; Buse, J.B.; For the LEADER Steering Committee on behalf the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016, 375, 311–322.
[23]	Gerstein, H.C.; Colhoun, H.M.; Dagenais, G.R.; Diaz, R.; Lakshmanan, M.; Pais, P.; Probstfield, J.; Riesmeyer, J.S.; Riddle, M.C.; Rydén, L.; Xavier, D.; Atisso, C.M.; Dyal, L.; Hall, S.; Rao-Melacini, P.; Wong, G.; Avezum, A.; Basile, J.; Chung, N.; Conget, I.; Cushman, W.C.; Franek, E.; Hancu, N.; Hanefeld, M.; Holt, S.; Jansky, P.; Keltai, M.; Lanas, F.; Leiter, L.A.; Lopez-Jaramillo, P.; Cardona Munoz, E.G.; Pirags, V.; Pogosova, N.; Raubenheimer, P.J.; Shaw, J.E.; Sheu, W.H.; Temelkova-Kurktschiev, T. Dulaglutide and cardiovascular outcomes in type 2 diabetes: a double–blind, randomised placebo-controlled trial. Lancet. 2019, 394, 121–130.
[24]	Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz, F.G.; Jódar, E.; Leiter, L.A.; Lingvay, I.; Rosenstock, J.; Seufert, J.; Warren, M.L.; Woo, V.; Hansen, O.; Holst, A.G.; Pettersson, J.; Vilsbøll, T.; For the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2016, 375, 1834–1844.
[25]	Pfeffer, M.A.; Claggett, B.; Diaz, R.; Dickstein, K.; Gerstein, H.C.; Køber, L.V.; Lawson, F.C.; Ping, L.; Wei, X.D.; Lewis, E.F.; Maggioni, A.P.; McMurray, J.J.V.; Probstfield, J.L.; Riddle, M.C.; Solomon, S.D.; Tardif, J.C. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 2015, 373, 2247–2257.
[26]	Holman, R.R.; Bethel, M.A.; Mentz, R.J.; Thompson, V.P.; Lokhnygina, Y.; Buse, J.B.; Chan, J.C.; Choi, J.; Gustavson, S.M.; Iqbal, N.; Maggioni, A.P.; Marso, S.P.; Öhman, P.; Pagidipati, N.J.; Poulter, N.; Ramachandran, A.; Zinman, B.; Hernandez, A.F.; For the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2017, 377, 1228–1239.
[27]	Hernandez, A.F.; Green, J.B.; Janmohamed, S.; D’Agostino, R.B.; Granger, C.B.; Jones, N.P.; Leiter, L.A.; Rosenberg, A.E.; Sigmon, K.N.; Somerville, M.C.; Thorpe, K.M.; McMurray, J.J.V.; Del Prato, S. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018, 392, 1519–1529.
[28]	Sorli, C.; Harashima, S.I.; Tsoukas, G.M.; Unger, J.; Karsbøl, J.D.; Hansen, T.; Bain, S.C. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5, 251–260.
[29]	Ahrén, B.; Masmiquel, L.; Kumar, H.; Sargin, M.; Karsbøl, J.D.; Jacobsen, S.H.; Chow, F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017, 5, 341–354.
[30]	Ahmann, A.J.; Capehorn, M.; Charpentier, G.; Dotta, F.; Henkel, E.; Lingvay, I.; Holst, A.G.; Annett, M.P.; Aroda, V.R. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018, 41, 258–266.
[31]	Aroda, V.R.; Bain, S.C.; Cariou, B.; Piletič, M.; Rose, L.; Axelsen, M.; Rowe, E.; DeVries, J.H. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5, 355–366.
[32]	Rodbard, H.W.; Lingvay, I.; Reed, J.; de la Rosa, R.; Rose, L.; Sugimoto, D.; Araki, E.; Chu, P.L.; Wijayasinghe, N.; Norwood, P. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J. Clin. Endocrinol. Metab. 2018, 103, 2291–2301.
[33]	Pratley, R.E.; Aroda, V.R.; Lingvay, I.; Lüdemann, J.; Andreassen, C.; Navarria, A.; Viljoen, A. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018, 6, 275–286.
[34]	Lingvay, I.; Catarig, A.M.; Frias, J.P.; Kumar, H.; Lausvig, N.L.; le Roux, C.W.; Thielke, D.; Viljoen, A.; McCrimmon, R.J. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019, 7, 834–844.
[35]	Zinman, B.; Bhosekar, V.; Busch, R.; Holst, I.; Ludvik, B.; Thielke, D.; Thrasher, J.; Woo, V.; Philis-Tsimikas, A. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019, 7, 356–367.
[36]	Capehorn, M.S.; Catarig, A.M.; Furberg, J.K.; Janez, A.; Price, H.C.; Tadayon, S.; Vergès, B.; Marre, M. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020, 46, 100–109.
[37]	Kellerer, M.; Kaltoft, M.S.; Lawson, J.; Nielsen, L.L.; Strojek, K.; Tabak, Ö.; Jacob, S. Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial. Diabetes Obes. Metab. 2022, 24, 1788–1799.
[38]	Ji, L.N.; Dong, X.L.; Li, Y.M.; Li, Y.F.; Lim, S.; Liu, M.; Ning, Z.; Rasmussen, S.; Skjøth, T.V.; Yuan, G.Y.; Eliaschewitz, F.G. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes. Metab. 2021, 23, 404–414.
[39]	Wilding, J.P.H.; Batterham, R.L.; Calanna, S.; Davies, M.; Van Gaal, L.F.; Lingvay, I.; McGowan, B.M.; Rosenstock, J.; Tran, M.T.D.; Wadden, T.A.; Wharton, S.; Yokote, K.; Zeuthen, N.; Kushner, R.F.; For the STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 2021, 384, 989–1002.
[40]	Davies, M.; Færch, L.; Jeppesen, O.K.; Pakseresht, A.; Pedersen, S.D.; Perreault, L.; Rosenstock, J.; Shimomura, I.; Viljoen, A.; Wadden, T.A.; Lingvay, I. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021, 397, 971–984.
[41]	Wadden, T.A.; Bailey, T.S.; Billings, L.K.; Davies, M.; Frias, J.P.; Koroleva, A.; Lingvay, I.; O'Neil, P.M.; Rubino, D.M.; Skovgaard, D.; Wallenstein, S.O.R.; Garvey, W.T.; For the STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021, 325, 1403–1413.
[42]	Rubino, D.; Abrahamsson, N.; Davies, M.; Hesse, D.; Greenway, F.L.; Jensen, C.; Lingvay, I.; Mosenzon, O.; Rosenstock, J.; Rubio, M.A.; Rudofsky, G.; Tadayon, S.; Wadden, T.A.; Dicker, D.; For the STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325, 1414–1425.
[43]	Wharton, S.; Batterham, R.L.; Bhatta, M.; Buscemi, S.; Christensen, L.N.; Frias, J.P.; Jódar, E.; Kandler, K.; Rigas, G.; Wadden, T.A.; Garvey, W.T. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: step 5. Obesity. 2023, 31, 703–715.
[44]	Kadowaki, T.; Isendahl, J.; Khalid, U.; Lee, S.Y.; Nishida, T.; Ogawa, W.; Tobe, K.; Yamauchi, T.; Lim, S. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022, 10, 193–206.
[45]	Rubino, D.M.; Greenway, F.L.; Khalid, U.; O'Neil, P.M.; Rosenstock, J.; Sørrig, R.; Wadden, T.A.; Wizert, A.; Garvey, W.T.; For the STEP 8 Investigators. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022, 327, 138–150.
[46]	Weghuber, D.; Barrett, T.; Barrientos-Pérez, M.; Gies, I.; Hesse, D.; Jeppesen, O.K.; Kelly, A.S.; Mastrandrea, L.D.; Sørrig, R.; Arslanian, S.; For the STEP TEENS Investigators. Once-weekly semaglutide in adolescents with obesity. N. Engl. J. Med. 2022, 387, 2245–2257.
[47]	Zinman, B.; Nauck, M.A.; Bosch-Traberg, H.; Frimer-Larsen, H.; Ørsted, D.D.; Buse, J.B.; The LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide and glycaemic outcomes in the LEADER trial. Diabetes Ther. 2018, 9, 2383–2392.
[48]	Tack, C.; Jacob, S.; Desouza, C.; Bain, S.; Buse, J.; Nauck, M.; Petrie, J.; Poulter, N.; Pratley, R.; Stegmann, H.; Bosch‐Traberg, H.; Startseva, E.; Zinman, B. Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: evidence from the LEADER trial. Diabetes Obes. Metab. 2019, 21, 2450–2458.
[49]	Garvey, W.T.; Birkenfeld, A.L.; Dicker, D.; Mingrone, G.; Pedersen, S.D.; Satylganova, A.; Skovgaard, D.; Sugimoto, D.; Jensen, C.; Mosenzon, O. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020, 43, 1085–1093.
[50]	Pi-Sunyer, X.; Astrup, A.; Fujioka, K.; Greenway, F.; Halpern, A.; Krempf, M.; Lau, D.C.W.; le Roux, C.W.; Ortiz, R.V.; Jensen, C.B.; Wilding, J.P.H.; For the SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 2015, 373, 11–22.
[51]	Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.E.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S.; Steinberg, W.M.; Stockner, M.; Zinman, B.; Bergenstal, R.M.; Buse, J.B. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016, 375, 311–322.
[52]	Mann, J.F.E.; Ørsted, D.D.; Brown-Frandsen, K.; Marso, S.P.; Poulter, N.R.; Rasmussen, S.; Tornøe, K.; Zinman, B.; Buse, J.B.; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 2017, 377, 839–848.
[53]	Kwan Anita, Y.M.; Gerstein Hertzel, C.; Jan, B.; Denis, X.; Maldonado Juan, M.; Sohini, R.; Manige, K. HbA1c reduction in dulaglutide-treated patients irrespective of duration of diabetes, microvascular disease, and BMI: a post hoc analysis from the REWIND trial. Diabetes Care. 2022, 45, 547–554.
[54]	Franek, E.; Gerstein, H.; Riddle, M.; Nicolay, C.; Hickey, A.; Botros, F.; Loo, L.S. Efficacy and safety outcomes of dulaglutide by baseline HbA1c: a post hoc analysis of the REWIND trial. Diabetes Obes. Metab. 2022, 24, 1753–1761.
[55]	Konig, M.; Riddle, M.; Colhoun, H.; Branch, K.; Atisso, C.; Lakshmanan, M.; Mody, R.; Raha, S.; Gerstein, H. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovasc. Diabetol. 2021, 20, 194.
[56]	ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Hilliard, M.E.; Isaacs, D.; Johnson, E.L.; Kahan, S.; Khunti, K.; Leon, J.; Lyons, S.K.; Perry, M.L.; Prahalad, P.; Pratley, R.E.; Seley, J.J.; Stanton, R.C.; Gabbay, R.A. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023, 46, S140–S157.
[57]	Gerstein, H.; Hart, R.; Colhoun, H.; Diaz, R.; Lakshmanan, M.; Botros, F.; Probstfield, J.; Riddle, M.; Rydén, L.; Atisso, C.; Dyal, L.; Hall, S.; Avezum, Á.; Basile, J.; Conget, I.; Cushman, W.; Hancu, N.; Hanefeld, M.; Janský, P.; Keltai, M.; Lanas, F.; Leiter, L.A.; López-Jaramillo, P.; Munoz, E.G.C.; Pogosova, N.; Raubenheimer, P.; Shaw, J.; Sheu, W.; Temelkova-Kurktschiev, T. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 2020, 8, 106–114.
[58]	Gerstein, H.C.; Colhoun, H.M.; Dagenais, G.R.; Diaz, R.; Lakshmanan, M.; Pais, P.; Probstfield, J.; Botros, F.T.; Riddle, M.C.; Rydén, L.; Xavier, D.; Atisso, C.M.; Dyal, L.; Hall, S.; Rao-Melacini, P.; Wong, G.; Avezum, A.; Basile, J.; Chung, N.; Conget, I.; Cushman, W.C.; Franek, E.; Hancu, N.; Hanefeld, M.; Holt, S.; Jansky, P.; Keltai, M.; Lanas, F.; Leiter, L.A.; Lopez-Jaramillo, P.; Munoz, E.G.C.; Pirags, V.; Pogosova, N.; Raubenheimer, P.J.; Shaw, J.E.; Sheu, W.H.H.; Temelkova-Kurktschiev, T.; For the REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019, 394, 131–138.
[59]	Cukierman-Yaffe, T.; Gerstein, H.C.; Colhoun, H.M.; Diaz, R.; García-Pérez, L.E.; Lakshmanan, M.; Bethel, A.; Xavier, D.; Probstfield, J.; Riddle, M.C.; Rydén, L.; Atisso, C.M.; Hall, S.; Rao-Melacini, P.; Basile, J.; Cushman, W.C.; Franek, E.; Keltai, M.; Lanas, F.; Leiter, L.A.; Temelkova-Kurktschiev, T. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020, 19, 582–590.
[60]	Srikanth, V.; Sinclair, A.J.; Hill-Briggs, F.; Moran, C.; Biessels, G.J. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol. 2020, 8, 535–545.
[61]	Vilsbøll, T.; Bain, S.C.; Leiter, L.A.; Lingvay, I.; Matthews, D.; Simó, R.; Helmark, I.C.; Wijayasinghe, N.; Larsen, M. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes. Metab. 2018, 20, 889–897.
[62]	Mann, J.F.E.; Hansen, T.; Idorn, T.; Leiter, L.A.; Marso, S.P.; Rossing, P.; Seufert, J.; Tadayon, S.; Vilsbøll, T. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020, 8, 880–893.
[63]	Rossing, P.; Baeres, F.M.M.; Bakris, G.; Bosch-Traberg, H.; Gislum, M.; Gough, S.C.L.; Idorn, T.; Lawson, J.; Mahaffey, K.W.; Mann, J.F.E.; Mersebach, H.; Perkovic, V.; Tuttle, K.; Pratley, R. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol. Dial. Transplant. 2023, 38, 2041–2051.
[64]	Yuan, X.Y.; Guo, X.H.; Zhang, J.Q.; Dong, X.L.; Lu, Y.B.; Pang, W.Y.; Gu, S.H.; Niemoeller, E.; Ping, L.; Nian, G.W.; Souhami, E.; Investigators, L.L.C. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan-L-CN randomized controlled trial. Diabetes Obes. Metab. 2022, 24, 2182–2191.
[65]	Blonde, L.; Anderson, J.E.; Chava, P.; Dendy, J.A. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr. Med. Res. Opin. 2019, 35, 793–804.
[66]	Muskiet, M.H.A.; Tonneijck, L.; Huang, Y.; Liu, M.Z.; Saremi, A.; Heerspink, H.J.L.; van Raalte, D.H. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018, 6, 859–869.
[67]	Bethel, M.A.; Mentz, R.J.; Merrill, P.; Buse, J.B.; Chan, J.C.; Goodman, S.G.; Iqbal, N.; Jakubonienė, N.; Katona, B.G.; Lokhnygina, Y.; Lopes, R.D.; Maggioni, A.P.; Ohman, P.K.; Poulter, N.R.; Ramachandran, A.; Tankova, T.; Zinman, B.; Hernandez, A.F.; Holman, R.R. Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL). Diabetes. 2018, 67, 552-P.
[68]	Piccini, S.; Favacchio, G.; Panico, C.; Morenghi, E.; Folli, F.; Mazziotti, G.; Lania, A.G.; Mirani, M. Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. Cardiovasc. Diabetol. 2023, 22, 69.
[69]	Sharma, A.; Mariam, A.; Zacherle, E.; Milinovich, A.; Bauman, J.; Sugano, D.; Noone, J.; Rajpura, J.; Zimmerman, R.; Burguera, B.; Kattan, M.; Misra-Hebert, A.; Pantalone, K.; Rotroff, D.M. Elucidating the role of weight loss and glycemia with observed benefits of GLP-1 receptor agonist treatment in patients with T2D. Diabetes. 2023, 72, 795-P.
[70]	Liu, L.L.; Chen, J.; Wang, L.; Chen, C.; Chen, L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front. Endocrinol. 2022, 13, 1043789.
[71]	Shetty, R.; Basheer, F.T.; Poojari, P.G.; Thunga, G.; Chandran, V.P.; Acharya, L.D. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab. Syndr. 2022, 16, 102427.
[72]	Nreu, B.; Dicembrini, I.; Tinti, F.; Mannucci, E.; Monami, M. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol. 2023, 48, 206–213.
[73]	Bezin, J.; Gouverneur, A.; Pénichon, M.; Mathieu, C.; Garrel, R.; Hillaire-Buys, D.; Pariente, A.; Faillie, J.L. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023, 46, 384–390.
[74]	Gudin, B.; Ladhari, C.; Robin, P.; Laroche, M.L.; Babai, S.; Hillaire-Buys, D.; Faillie, J.L. Incretin-based drugs and intestinal obstruction: a pharmacovigilance study. Therapies. 2020, 75, 641–647.
[75]	El, K.; Douros, J.D.; Willard, F.S.; Novikoff, A.; Sargsyan, A.; Perez-Tilve, D.; Wainscott, D.B.; Yang, B.; Chen, A.; Wothe, D.; Coupland, C.; Tschöp, M.H.; Finan, B.; D’Alessio, D.A.; Sloop, K.W.; Müller, T.D.; Campbell, J.E. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat. Metab. 2023, 5, 945–954.
[76]	Rosenstock, J.; Wysham, C.; Frías, J.P.; Kaneko, S.; Lee, C.J.; Fernández Landó, L.; Mao, H.Z.; Cui, X.W.; Karanikas, C.A.; Thieu, V.T. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398, 143–155.
[77]	Frías, J.P.; Davies, M.J.; Rosenstock, J.; Pérez Manghi, F.C.; Landó, L.F.; Bergman, B.K.; Liu, B.; Cui, X.W.; Brown, K.; for the SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 2021, 385, 503–515.
[78]	Ludvik, B.; Giorgino, F.; Jódar, E.; Frias, J.P.; Fernández Landó, L.; Brown, K.; Bray, R.; Rodríguez, Á. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021, 398, 583–598.
[79]	Del Prato, S.; Kahn, S.E.; Pavo, I.; Weerakkody, G.J.; Yang, Z.Y.; Doupis, J.; Aizenberg, D.; Wynne, A.G.; Riesmeyer, J.S.; Heine, R.J.; Wiese, R.J. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021, 398, 1811–1824.
[80]	Dahl, D.; Onishi, Y.; Norwood, P.; Huh, R.; Bray, R.; Patel, H.; Rodríguez, Á. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022, 327, 534–545.
[81]	Garvey, W.T.; Frias, J.P.; Jastreboff, A.M.; le Roux, C.W.; Sattar, N.; Aizenberg, D.; Mao, H.Z.; Zhang, S.Y.; Ahmad, N.N.; Bunck, M.C.; Benabbad, I.; Zhang, X.M.; Investigators, S.2. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023, 402, 613–626.
[82]	Jastreboff, A.M.; Kaplan, L.M.; Frías, J.P.; Wu, Q.W.; Du, Y.; Gurbuz, S.; Coskun, T.; Haupt, A.; Milicevic, Z.; Hartman, M.L. Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N. Engl. J. Med. 2023, 389, 514–526.